Download PDF
Drug Res (Stuttg) 2014; 64(08): 424-428
DOI: 10.1055/s-0033-1361107
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Effects of Unprocessed vs. Cooked-processed Gastrodia elata on Cytochrome P450 Enzymes in Rats

Y. Huang
1   Department of General Surgery of Wenzhou People’s Hospital, Wenzhou, China
,
S.-L. Zheng
2   Department of Pediatric Surgery of the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
,
Z.-S. Xu
3   Department of Hematology of the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
,
Y. Hou
4   Department of Ultrasound Imaging of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
› Author Affiliations
Further Information

Publication History

received 07 October 2013

accepted 07 November 2013

Publication Date:
27 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Context:

Gastrodia elata Blume (GE) has been used as a traditional herb and is considered one of the most important medicinal plants in Oriental countries since centuries.

Objective:

The purpose of this study was to find out the differences between the effects of unprocessed and cooked-processed GE (CGE) on rat cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C9 and CYP3A4) by using cocktail probe drugs in vivo.

Methods:

A cocktail solution at a dose of 5 mL/kg, which contained phenacetin (20 mg/kg), tolbutamide (5 mg/kg) and midazolam (10 mg/kg), was orally administration to rats treated with GE or CGE for 14 days orally. Blood samples were collected at a series of time-points and the concentrations of probe drugs in plasma were determined by HPLC-MS/MS. The corresponding pharmacokinetic parameters were calculated by the software of DAS 2.0.

Results:

Both GE and CGE did not have significant influences on the pharmacokinetic parameters of phenacetin (P>0.05). In addition, CGE decreased the t1/2, Cmax, AUC(0–∞) of tolbutamide (P<0.05) and it increased CL significantly (P<0.01). Furthermore, the trend in CGE was similar but far more significant than GE on t1/2, Cmax, AUC(0–∞), and other parameters of midazolam (P<0.05).

Conclusions:

In conclusion, GE and CGE had no effects on rat CYP1A2. GE did not affect CYP2C9 activity, but CGE induced the CYP2C9 activity. Moreover, CGE was more potent than GE for inhibitory effect on CYP3A4 activity. These results provide useful scientific data for the safe clinical application of either extract of GE or in combination with other drugs, which should lack the side effects induced by other herb-drug interactions.

Key words

GE - CGE - CYP - interaction
 

  • References

  • 1 Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569-1575
    CrossrefPubMedGoogle Scholar
  • 2 Su D, Li L. Trends in the use of complementary and alternative medicine in the United States: 2002–2007. J Health Care Poor Underserved 2011; 22: 296-310
    PubMedGoogle Scholar
  • 3 Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170-178
    CrossrefPubMedGoogle Scholar
  • 4 Posadzki P, Watson L, Ernst E. Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol 2013; 75: 603-618
    PubMedGoogle Scholar
  • 5 Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580
    CrossrefPubMedGoogle Scholar
  • 6 Pelkonen O, Turpeinen M, Hakkola J et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715
    CrossrefPubMedGoogle Scholar
  • 7 Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999; 33: 426-428
    CrossrefPubMedGoogle Scholar
  • 8 Usia T, Iwata H, Hiratsuka A et al. CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine 2006; 13: 67-73
    PubMedGoogle Scholar
  • 9 Foster BC, Vandenhoek S, Tang R et al. Effect of several Chinese natural health products of human cytochrome P450 metabolism. J Pharm Pharm Sci 2002; 5: 185-189
    PubMedGoogle Scholar
  • 10 Liu R, Tam TW, Mao J et al. The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir. J Pharm Pharm Sci 2010; 13: 43-55
    PubMedGoogle Scholar
  • 11 Scott IM, Leduc RI, Burt AJ et al. The inhibition of human cytochrome P450 by ethanol extracts of north american botanicals. Pharmaceutical Biology 2006; 44: 315-327
    CrossrefPubMedGoogle Scholar
  • 12 Ito K, Satoh T, Watanabe Y et al. Effects of Kampo medicines on CYP and P-gp activity in vitro. Biol Pharm Bull 2008; 31: 893-896
    CrossrefPubMedGoogle Scholar
  • 13 Rodeiro I, Donato MT, Jimenez N et al. Inhibition of human P450 enzymes by natural extracts used in traditional medicine. Phytother Res 2009; 23: 279-282
    CrossrefPubMedGoogle Scholar
  • 14 Budzinski JW, Foster BC, Vandenhoek S et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-282
    CrossrefPubMedGoogle Scholar
  • 15 Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95
    PubMedGoogle Scholar
  • 16 Jeong TY, Park BK, Cho JH et al. A prospective study on the safety of herbal medicines, used alone or with conventional medicines. J Ethnopharmacol 2012; 143: 884-888
    CrossrefPubMedGoogle Scholar
  • 17 Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 2005; 4: 355-378
    CrossrefPubMedGoogle Scholar
  • 18 Schachter SC. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics 2009; 6: 415-420
    CrossrefPubMedGoogle Scholar
  • 19 May BH, Lit M, Xue CC et al. Herbal medicine for dementia: a systematic review. Phytother Res 2009; 23: 447-459
    CrossrefPubMedGoogle Scholar
  • 20 Manavalan A, Feng L, Sze SK et al. New insights into the brain protein metabolism of Gastrodia elata-treated rats by quantitative proteomics. J Proteomics 2012; 75: 2468-2479
    CrossrefPubMedGoogle Scholar
  • 21 Zeng X, Zhang S, Zhang L et al. A study of the neuroprotective effect of the phenolic glucoside gastrodin during cerebral ischemia in vivo and in vitro. Planta Med 2006; 72: 1359-1365
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Kim DS, Kim JY, Han YS. Alzheimer’s disease drug discovery from herbs: neuroprotectivity from beta-amyloid (1–42) insult. J Altern Complement Med 2007; 13: 333-340
    CrossrefPubMedGoogle Scholar
  • 23 An H, Kim IS, Koppula S et al. Protective effects of Gastrodia elata Blume on MPP+-induced cytotoxicity in human dopaminergic SH-SY5Y cells. J Ethnopharmacol 2010; 130: 290-298
    CrossrefPubMedGoogle Scholar
  • 24 Chen PJ, Liang KC, Lin HC et al. Gastrodia elata Bl. Attenuated learning deficits induced by forced-swimming stress in the inhibitory avoidance task and Morris water maze. J Med Food 2011; 14: 610-617
    CrossrefPubMedGoogle Scholar
  • 25 Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005; 4: 825-833
    CrossrefPubMedGoogle Scholar
  • 26 Zientek M, Youdim K. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach. Methods Mol Biol 2013; 987: 11-23
    PubMedGoogle Scholar
  • 27 Lin W, Zhang J, Ling X et al. Evaluation of the effect of TM208 on the activity of five cytochrome P450 enzymes using on-line solid-phase extraction HPLC-DAD: a cocktail approach. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 923-924: 29-36
    CrossrefPubMedGoogle Scholar
  • 28 Zhou SF, Wang B, Yang LP et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42: 268-354
    CrossrefPubMedGoogle Scholar
  • 29 Wang B, Wang J, Huang SQ et al. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 2009; 10: 781-834
    CrossrefPubMedGoogle Scholar
  • 30 Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr Pharm Des 2008; 14: 990-1000
    CrossrefPubMedGoogle Scholar